tetano
Editor, Senior Moderator
Front Cardiovasc Med
. 2022 May 26;9:901245.
doi: 10.3389/fcvm.2022.901245. eCollection 2022.
Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes
Andrea Izquierdo-Marquisá[SUP] 1 2 [/SUP], Hector Cubero-Gallego[SUP] 1 3 [/SUP], Álvaro Aparisi[SUP] 1 3 [/SUP], Beatriz Vaquerizo[SUP] 1 2 3 4 [/SUP], Núria Ribas-Barquet[SUP] 1 2 4 [/SUP]
Affiliations
Abstract
COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a pandemic with high mortality and morbidity rates. Clinical manifestation is widely variable, including asymptomatic or mild respiratory tract illness to severe pneumonia and death. Myocardial injury is a significant pathogenic feature of COVID-19 and it is associated with worse in-hospital outcomes, mainly due to a higher number of hospital readmissions, with over 50% mortality. These findings suggest that myocardial injury would identify COVID-19 patients with higher risk during active infection and mid-term follow-up. Potential contributors responsible for myocardial damage are myocarditis, vasculitis, acute inflammation, type 1 and type 2 myocardial infarction. However, there are few data about cardiac sequelae and its long-term consequences. Thus, the optimal screening tool for residual cardiac sequelae, clinical follow-up, and the benefits of a specific cardiovascular therapy during the convalescent phase remains unknown. This mini-review explores the different mechanisms of myocardial injury related to COVID-19 and its short and long-term implications.
Keywords: COVID-19; SARS CoV-2; biomarkers; infection; inflammation; organ failure; prognosis.
. 2022 May 26;9:901245.
doi: 10.3389/fcvm.2022.901245. eCollection 2022.
Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes
Andrea Izquierdo-Marquisá[SUP] 1 2 [/SUP], Hector Cubero-Gallego[SUP] 1 3 [/SUP], Álvaro Aparisi[SUP] 1 3 [/SUP], Beatriz Vaquerizo[SUP] 1 2 3 4 [/SUP], Núria Ribas-Barquet[SUP] 1 2 4 [/SUP]
Affiliations
- PMID: 35722133
- PMCID: PMC9204594
- DOI: 10.3389/fcvm.2022.901245
Abstract
COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a pandemic with high mortality and morbidity rates. Clinical manifestation is widely variable, including asymptomatic or mild respiratory tract illness to severe pneumonia and death. Myocardial injury is a significant pathogenic feature of COVID-19 and it is associated with worse in-hospital outcomes, mainly due to a higher number of hospital readmissions, with over 50% mortality. These findings suggest that myocardial injury would identify COVID-19 patients with higher risk during active infection and mid-term follow-up. Potential contributors responsible for myocardial damage are myocarditis, vasculitis, acute inflammation, type 1 and type 2 myocardial infarction. However, there are few data about cardiac sequelae and its long-term consequences. Thus, the optimal screening tool for residual cardiac sequelae, clinical follow-up, and the benefits of a specific cardiovascular therapy during the convalescent phase remains unknown. This mini-review explores the different mechanisms of myocardial injury related to COVID-19 and its short and long-term implications.
Keywords: COVID-19; SARS CoV-2; biomarkers; infection; inflammation; organ failure; prognosis.